Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · Real-Time Price · USD

24.02

-0.27 (-1.11%)

At close: Aug 24, 2026, 4:00 PM EDT

23.78

-0.24 (-1.00%)

After-hours: Aug 24, 2026, 7:40 PM EDT

Viridian Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	164.99	212.38	99.59	102.83	155.58	42.3
Short-Term Investments	816.54	662.27	617.99	374.54	268.97	154.67
Cash & Short-Term Investments	981.53	874.65	717.58	477.37	424.55	196.97
Cash Growth	74.23%	21.89%	50.32%	12.44%	115.55%	54.31%
Receivables	75	-	-	0.1	0.1	0.45
Prepaid Expenses	24.74	19.58	20.88	9.01	6.52	2.65
Other Current Assets	-	-	-	-	-	0.1
Total Current Assets	1,081	894.23	738.46	486.48	431.17	200.16
Property, Plant & Equipment	4.85	3.65	3.44	3.34	2.94	2.06
Other Long-Term Assets	1.11	1.54	0.5	0.6	0.98	1.49
Total Assets	1,097	899.42	742.4	490.42	435.09	203.71

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	8.65	8.68	2.14	2.24	14.23	2.33
Accrued Expenses	54.24	60.89	44.93	23.17	18.11	10.4
Current Portion of Leases	0.72	0.75	0.51	0.84	0.61	0.52
Current Unearned Revenue	0.18	0.37	0.29	0.29	0.29	0.29
Other Current Liabilities	-	-	-	0.1	0.1	0.1
Total Current Liabilities	63.79	70.7	47.87	26.64	33.35	13.64
Long-Term Debt	242.16	49.94	20.58	20.21	4.65	-
Long-Term Leases	1.85	1.9	-	0.99	-	-
Long-Term Unearned Revenue	-	-	-	0.57	0.86	1.15
Other Long-Term Liabilities	127.33	54.72	2.31	-	1.17	1.21
Total Liabilities	435.14	177.25	70.76	48.4	40.03	15.99

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	1.13	1.02	0.81	0.54	0.41	0.24
Additional Paid-In Capital	2,135	1,927	1,478	960.54	741.07	412.1
Retained Earnings	-1,570	-1,338	-995.86	-725.91	-488.17	-358.3
Comprehensive Income & Other	-1.15	0.45	-0.01	0.34	-0.39	-0.16
Total Common Equity	564.07	590.11	482.75	235.51	252.92	53.88
Shareholders' Equity	662.1	722.17	671.64	442.02	395.06	187.72
Total Liabilities & Equity	1,097	899.42	742.4	490.42	435.09	203.71

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	244.73	52.59	21.1	22.04	5.26	0.52
Net Cash (Debt)	736.8	822.06	696.49	455.33	419.29	196.45
Net Cash Growth	36.38%	18.03%	52.96%	8.60%	113.44%	54.46%
Net Cash Per Share	7.63	9.69	10.26	10.17	13.07	16.48
Filing Date Shares Outstanding	113.29	102.21	81.48	62.77	42.9	25.91
Total Common Shares Outstanding	113.24	101.83	80.99	53.99	41.31	23.92
Working Capital	1,017	823.54	690.59	459.84	397.82	186.53
Book Value Per Share	4.98	5.80	5.96	4.36	6.12	2.25
Tangible Book Value	554.07	590.11	482.75	235.51	252.92	53.88
Tangible Book Value Per Share	4.89	5.80	5.96	4.36	6.12	2.25
Machinery	-	2.17	2.25	2.05	2.22	1.4
Leasehold Improvements	-	0.27	0.25	0.67	1.11	0.75

SEC Filings: 10-K · 10-Q